KR102778948B1 - Lsd1억제제의 염 및 이의 결정형 - Google Patents

Lsd1억제제의 염 및 이의 결정형 Download PDF

Info

Publication number
KR102778948B1
KR102778948B1 KR1020217005112A KR20217005112A KR102778948B1 KR 102778948 B1 KR102778948 B1 KR 102778948B1 KR 1020217005112 A KR1020217005112 A KR 1020217005112A KR 20217005112 A KR20217005112 A KR 20217005112A KR 102778948 B1 KR102778948 B1 KR 102778948B1
Authority
KR
South Korea
Prior art keywords
compound iii
crystalline form
compound
paragraph
lsd1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217005112A
Other languages
English (en)
Korean (ko)
Other versions
KR20210034058A (ko
Inventor
러러 자오
졘쥔 쑨
?컨? 쑨
링윈 우
수후이 천
Original Assignee
씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 filed Critical 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드
Publication of KR20210034058A publication Critical patent/KR20210034058A/ko
Application granted granted Critical
Publication of KR102778948B1 publication Critical patent/KR102778948B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217005112A 2018-07-20 2019-07-19 Lsd1억제제의 염 및 이의 결정형 Active KR102778948B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810804068.3 2018-07-20
CN201810804068 2018-07-20
PCT/CN2019/096842 WO2020015745A1 (zh) 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型

Publications (2)

Publication Number Publication Date
KR20210034058A KR20210034058A (ko) 2021-03-29
KR102778948B1 true KR102778948B1 (ko) 2025-03-07

Family

ID=69163657

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217005112A Active KR102778948B1 (ko) 2018-07-20 2019-07-19 Lsd1억제제의 염 및 이의 결정형

Country Status (8)

Country Link
US (1) US12024494B2 (enExample)
EP (1) EP3825309B1 (enExample)
JP (1) JP7358466B2 (enExample)
KR (1) KR102778948B1 (enExample)
CN (1) CN112424175B (enExample)
AU (1) AU2019303777B2 (enExample)
CA (1) CA3106484C (enExample)
WO (1) WO2020015745A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228146A1 (zh) * 2020-05-12 2021-11-18 石药集团中奇制药技术（石家庄）有限公司 一种lsd1抑制剂的用途
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116069221A (zh) * 2022-12-27 2023-05-05 北京字跳网络技术有限公司 媒体内容的展示方法、装置、电子设备和存储介质
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102947265A (zh) 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
CN103857393A (zh) 2011-03-25 2014-06-11 葛兰素史密斯克莱知识产权（第2号）有限公司 环丙基胺作为lsd1抑制剂
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
WO2017195216A1 (en) 2016-05-09 2017-11-16 Jubilant Biosys Limited Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705675B1 (fr) * 1993-05-27 1996-05-03 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
WO2010084160A1 (en) * 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
LT2598482T (lt) 2010-07-29 2018-07-10 Oryzon Genomics, S.A. Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
KR102710120B1 (ko) * 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
RU2763898C9 (ru) 2017-01-24 2022-03-18 Цспц Чжунци Фармасьютикал Текнолоджи (Шицзячжуан) Ко., Лтд. Ингибитор lsd1, а также способ его получения и его применение

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102947265A (zh) 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
CN103857393A (zh) 2011-03-25 2014-06-11 葛兰素史密斯克莱知识产权（第2号）有限公司 环丙基胺作为lsd1抑制剂
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
WO2017195216A1 (en) 2016-05-09 2017-11-16 Jubilant Biosys Limited Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors

Also Published As

Publication number Publication date
EP3825309A4 (en) 2022-03-23
US20210317096A1 (en) 2021-10-14
CN112424175A (zh) 2021-02-26
CA3106484A1 (en) 2020-01-23
AU2019303777A1 (en) 2021-02-11
JP7358466B2 (ja) 2023-10-10
CN112424175B (zh) 2022-10-28
AU2019303777B2 (en) 2023-01-19
JP2021530565A (ja) 2021-11-11
CA3106484C (en) 2024-06-25
US12024494B2 (en) 2024-07-02
KR20210034058A (ko) 2021-03-29
EP3825309A1 (en) 2021-05-26
EP3825309B1 (en) 2023-09-06
WO2020015745A1 (zh) 2020-01-23

Similar Documents

Publication Publication Date Title
KR102778948B1 (ko) Lsd1억제제의 염 및 이의 결정형
CN109563060B (zh) Ido1抑制剂及其制备方法和应用
HK1243409A1 (zh) 脯氨酰羟化酶抑制剂的晶体形态
BR112018008877B1 (pt) Compostos inibidores de ret, composição farmacêutica e usos dos referidos compostos
AU2020263390A1 (en) Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
EP3395817B1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
JP2022530812A (ja) Ｗｅｅ１阻害剤化合物の結晶形及びその応用
WO2012042078A1 (es) Derivados de cromeno
CN113956233B (zh) 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
CN110167554B (zh) 一种具有抗癌作用的化合物及其制备方法和应用
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма
CN117843638A (zh) 基于rsl3诱导gpx4蛋白降解的双功能分子化合物的制备与应用
WO2020228729A1 (zh) 喹唑啉酮类化合物的晶型及其制备方法
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
HK40038512A (en) Salt of lsd1 inhibitor and a polymorph thereof
HK40038512B (en) Salt of lsd1 inhibitor and a polymorph thereof
US12391653B2 (en) Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor
WO2021164789A1 (zh) 一种吡唑并嘧啶类化合物的晶型及其应用
TWI703134B (zh) 一種具有抗癌作用的化合物及其製備方法和應用（二）
EP4089086A1 (en) Crystal form of pyrrolidinyl urea derivative and application thereof
WO2025237404A1 (zh) 一种mc4r拮抗剂的多晶型物及其制备方法和应用
WO2024213088A1 (zh) 嘧啶三并环衍生物的结晶及用途
WO2020007329A1 (zh) Hdac6选择性抑制剂的晶型及其应用
CN116120322A (zh) 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220328

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240426

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250109

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250305

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250305

End annual number: 3

Start annual number: 1

PG1601 Publication of registration